source
- Regeneron's Pasatru receives FDA approval for ultra-rare bone-growth disease FOPRegeneron Pharmaceuticals has secured FDA approval for Pasatru, a therapy aimed at treating fibrodysplasia ossificans progressiva (FOP), an ultra‑rare condition in which bone forms in soft tissues.…
- Moderna and Merck report success for personalized mRNA vaccine in late-stage melanoma trialModerna and Merck announced that their personalized mRNA cancer vaccine succeeded in a late-stage melanoma study. The vaccine, called intismeran, was evaluated in a randomized Phase 3 trial, the fi…